Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marianne T Sweetser

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Orphanet Journal of Rare Diseases|October 3, 2024
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension studyEliane Sardh, Manisha Balwani, David C Rees, et al.
Orphanet Journal of Rare Diseases|August 26, 2022
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION studyBruce Wang, Paolo Ventura, Kei-Ichiro Takase, et al.
Clinical Therapeutics|March 2, 2006
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe, Kim Papp, David Gratton, et al.
Expert Review of Gastroenterology & Hepatology|August 5, 2022
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiranPaolo Ventura, Eliane Sardh, Nicola Longo, et al.
Clinical Pharmacology and Therapeutics|June 30, 2020
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy SubjectsBahru A Habtemariam, Verena Karsten, Husain Attarwala, et al.
Journal of Inherited Metabolic Disease|September 7, 2022
EXPLORE B: A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptomsDavid Cassiman, Raili Kauppinen, Susana Monroy, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisRalf Gold, Ludwig Kappos, Douglas L Arnold, et al.
The New England Journal of Medicine|July 19, 2023
Zilebesiran, an RNA Interference Therapeutic Agent for HypertensionAkshay S Desai, David J Webb, Jorg Taubel, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 28, 2024
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO studyKon-Ping Lin, Chih-Chao Yang, Yi-Chung Lee, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisRobert J Fox, David H Miller, J Theodore Phillips, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Orphanet Journal of Rare Diseases|October 3, 2024
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension studyEliane Sardh, Manisha Balwani, David C Rees, et al.
Orphanet Journal of Rare Diseases|August 26, 2022
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION studyBruce Wang, Paolo Ventura, Kei-Ichiro Takase, et al.
Clinical Therapeutics|March 2, 2006
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe, Kim Papp, David Gratton, et al.
Expert Review of Gastroenterology & Hepatology|August 5, 2022
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiranPaolo Ventura, Eliane Sardh, Nicola Longo, et al.
Clinical Pharmacology and Therapeutics|June 30, 2020
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy SubjectsBahru A Habtemariam, Verena Karsten, Husain Attarwala, et al.
Journal of Inherited Metabolic Disease|September 7, 2022
EXPLORE B: A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptomsDavid Cassiman, Raili Kauppinen, Susana Monroy, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisRalf Gold, Ludwig Kappos, Douglas L Arnold, et al.
The New England Journal of Medicine|July 19, 2023
Zilebesiran, an RNA Interference Therapeutic Agent for HypertensionAkshay S Desai, David J Webb, Jorg Taubel, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 28, 2024
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO studyKon-Ping Lin, Chih-Chao Yang, Yi-Chung Lee, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisRobert J Fox, David H Miller, J Theodore Phillips, et al.
Pageof 4